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Available online 23 April 2009Introduction: To support clinical practice as well as clinical research, self-rating scales have
been developed to evaluate the effects and side effects of antipsychotic treatment. The aim of
this study is to compare the psychometric properties and other characteristics of frequently
used self-rating scales, and also to study their relationship to subjective quality of life.
Method: Four self-rating scales designed to evaluate the treatment effects of antipsychotics
were identiﬁed through a MEDLINE and cross-references search: The Drug Attitude Inventory
(DAI-10), The Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS), Subjective
Well-being to Neuroleptics (SWN) and the recently developed Subjects' Reaction to
Antipsychotics questionnaire (SRA). Three hundred and twenty patients with schizophrenia
who were treated with antipsychotics completed these questionnaires, including a quality of
life instrument, the WHO-QoLBREF.
Results: The self-rating scales differed in scope, number of items and subscales (total and
subscale scores), but showed an acceptable internal reliability (Cronbach's alphas varying
between .64 and .93) except for the DAI-10 (.52), and all were easy to complete (in less than
20 min). They did not strongly correlate with each other, except for the LUNSERS and SRA
undesired experiences subscale (r=.68, pb .01). All correlations with quality of life were
statistically signiﬁcant, but were especially so for the SWN (.78, pb .01).
Conclusion: Clinicians interested in the experience of the effects and side effects of antipsychotic
medication in their patients are well advised to carefully consider the pros and cons of the
available rating scales. They differ with respect to their internal reliability, concurrent and
conceptual validity, as well as with respect to desired and undesired effects, aspects of quality of
life, and attribution to medication. The choice also depends on its intended use, whether in
clinical practice or in research or in both.




Most patients with schizophrenia need pharmacological
treatment for many years. Unfortunately, almost all patients
also experience undesirable side effects during this treatment
with antipsychotics (Fakhoury et al., 2001), which frequently
result in an early discontinuation or switching of medication
(Lieberman et al., CATIE-study 2005; Kahn et al., 2008; Ücokiatry (UCP), University
e Netherlands, PO Box
0 3613972; fax: +31 50
gtering).
All rights reserved.and Gaebel, 2008). During the last three decades, interest in
the inﬂuence of antipsychotic treatment and other treatment-
related variables on patients' quality of life has been growing
(e.g., Voruganti et al., 1997). The symptomatic treatment of
schizophrenia with antipsychotic medication, therefore,
should aim at the best quality of life by decreasing the
severity of psychotic symptoms (desired effect) with no, or as
few as possible, undesired effects. The effects of antipsychotic
medication reported by patients is one of the factors
associated with quality of life(QoL) (Naber, 1998; Voruganti
et al., 2002; Hofer et al., 2004).
Until 1960, the evaluation of antipsychotic treatment was
mainly based on the rather unstandardized assessment by
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the course of time. In the late twentieth century, structured
interviewswere introduced in order to improve the evaluation of
treatment effects, but they required a great deal of training and
proved to be too time consuming in clinical practice. Moreover,
patients' subjective quality of life also became a focus of interest
in this evaluation process (Katschnig et al., 1997). Self-rating
instruments have been developed and several studies have
demonstrated that schizophrenia patients are capable of com-
pleting such self-reports in a reliable way (Naber, 1998).
All studied instruments were included in a study targeted
to investigate the reliability and validity of the newly
developed Subjects Reaction to Antipsychotics questionnaire
as principal objective. Details on the design of this study can
be found in earlier publications (Wolters et al., 2003, 2006).
The design of the original study anticipated the comparison of
the included questionnaires, including their correlation with
quality of life, in order to investigate the pros and cons of the
questionnaires for clinical practice and research.
2. Methods
A MEDLINE search for 1997–2006 was performed using the
terms antipsychotics, psychometrics and self-rating. We also
checked cross-references.We found22papers that used avariety
of scales, only four of which were relevant for our purpose: the
self-rating of subjectively experienced effects and side effects of
antipsychotic medication. The scales we identiﬁed are described
below.
The Drugs Attitude Inventory (DAI; Hogan et al., 1983) was
constructed by collecting statements from schizophrenia
patients about their antipsychoticmedication. These statements
reﬂected both subjective feelings and attitudes. The scale was
designed topredict drug compliance. Thirty itemswere found to
discriminate signiﬁcantly between compliant and non-compli-
ant patients. This original DAI-30 had seven subscales:
Subjective Positive (8 items; e.g., “feel more normal, get along
better with people”), Subjective Negative (6 items; e.g., “cannot
concentrate”), Health/Illness (3 items; e.g., “take only when
sick”), Physician (2 items; e.g., “I know better than the doctor”),
Control (2 items; e.g., “pressure to take medication”), Preven-
tion (2 items; e.g., “by staying on medication I can prevent a
breakdown”) andHarm(2 items; e.g., “medicationwill harmmy
body”). Analysis of reliability as well as discriminant and factor
analysis was performed on data from 150 outpatients, approxi-
mately 40 years old, with an average of six hospitalizations and
an admission duration of nearly four years. Ten items, which
produced amaximumgroup separation between compliant and
non-compliant patients, constituted the DAI-10. Six items were
drawn from the ﬁrst two subjective subscales and four items
from the attitude scales. Each item was scored as yes (1) or no
(0). The total score ranged from 1 to 10, with higher scores
indicating a positive attitude to antipsychotic medication.
The Liverpool University Neuroleptic Side Effect Rating Scale
(LUNSERS; Day et al., 1995) was developed as a self-rating scale
for “measuring side effects of neuroleptic drugs.” Its items are
mainly derived from the physician-rated UKU scale requiring
training and 60 min administering time (Lingjaerde et al., 1987).
The LUNSERS has 41 items, covering psychological, neurological,
autonomic, hormonal and other miscellaneous side effects. In
addition, ten “red herring” items, that is, symptoms that do notdirectly relate to known antipsychotic side effects, were included
to indicate the accuracy of the patient self-report. Items were
ratedonaﬁve-point scale from(0) “not at all” to (4) “verymuch.”
The total sideeffect score ranged from0to164,withhigher scores
indicatingmore side effects. Validity and reliabilitywere tested in
a group of 50 male and female patients with a mean age of
46 years and 16 years of antipsychotic use, along with a group of
50 healthy controls. The validity of the LUNSERS was tested
against the UKU.
The Subjective Well-being on Neuroleptics questionnaire
(SWN) developed by Naber et al. (1994) and Naber (1995)
measures the subtle subjective changes — possibly related to
the use of antipsychotics — in the area of emotions, clarity of
thinking, spontaneity and functioning. The Likert scale with
six response categories (1–6) consists of 38 items based on
clinical experience and on an examination of item-scale
correlations, variance and subjective importance. There are
ﬁve subscales: Emotional Regulation (8 items; e.g., “my
emotions are steady and balanced”), Self-Control (6 items;
e.g., “my thoughts always revolve around the same things”),
Mental Functioning (8 items; e.g., “I ﬁnd it easy to think”),
Social Integration (8 items; e.g., “I feel lost and alone”) and
Physical Functioning (7 items; e.g., “I feel weak and
exhausted”). The total score ranges from 38 to 190, with
higher scores indicating greater well-being. Psychometric
properties (stability, consistency, sensitivity, relationship to
compliance, objective psychopathology, extra-pyramidal
symptoms and quality of life) has been established in a
group of 280 inpatients and outpatients, with 32 years of age
on average and a duration of illness of six years (Naber, 1995).
The Subjects Response to Antipsychotics questionnaire (SRA,
Wolters et al., 2006) measures “all responses to changes in
mental, physical and social domains attributed by the patient to
his/her current antipsychotic medication.” Items were collected
by interviewing patients about changes and responses they
attributed to the medication (Wolters et al., 2003). The full SRA
questionnaire is a 74-item instrument with eight subscales, with
56 items in total. Subscales of the SRA are: Recovery (24 items;
e.g., “I ammore stable”), Weight gain (4 items; e.g., “I have more
of an appetite”), Sexual anhedonia (3 items; e.g., “I have less need
for sex”), Sedation (6 items; e.g., “I react slower”), Affective
ﬂattening (3 items; e.g., “my emotions are more level”), Extra-
pyramidal side effects (5 items; e.g., “my muscles tense more”),
Diminished sociability (6 items; e.g., “I have less need for social
contacts”), and Increased sleep (3 items; e.g., “I sleep toomuch”).
Eighteen miscellaneous items not belonging to a dimensional
scalewerenot taken into account in this study. Thedesiredeffects
or positive responsewere covered by the 24 Recovery items, and
the undesired effects or negative response by 32 items from the
other subscales. Items were scored on a three-point scale from
(1) no, (2) yes to a certain degree to (3) yes to a high degree.
Higher scores indicated more effects attributed to the anti-
psychotic medication by the patient. Validity, consistency and
reliability were established in a group of 320 male and female
inpatients and outpatients (see below andWolters et al., 2006).
2.1. Subjects
A cross-sectional study was performed including 234male
and 86 female inpatients and outpatients with a diagnosis
within the schizophrenia spectrum from eight mental health
Table 1
Characteristics and psychometric properties of self-rating instruments for side effects of antipsychotic treatment among 320 inpatients and outpatients.
Scales DAI-10 LUNSERS SWN SRA
Aims of
evaluation
Attitudes and beliefs towards doctor, health,




Changes in emotionality, clarity of
thinking, spontaneity and
functioning
Responses to changes in mental, physical




10 41 38 56
Number of
subscales
1 1 1 total 2 total
5 subscales 7 subscales
Time to
complete







Total score: .91 D (desired): .93








⁎DAI = Drugs Attitude Inventory; LUNSERS (excluding 10 “red herring” items) = Liverpool University Neuroleptic Side Effect Rating Scale; SWN = Subjective
Well-being on Neuroleptics (subscales: PH: Physical Functioning; SI: Social Integration; SC: Self-Control; ER: Emotional Regulation; MF: Mental Functioning); SRA
(excluding 18 miscellaneous items) = Subjects' Response to Antipsychotics questionnaire, excluding 18 miscellaneous items (subscales: D: desired or recovery;
and U: undesired; WG: Weight gain; SA: Sexual anhedonia; S: Sedation; AF: Affective ﬂattening; DS: Diminished sociability; IS: Increased sleep; ES: Extra-
pyramidal side effects).
Table 2
Spearman correlations between the total scores of self-rating instruments for
the side effects of antipsychotic treatment and quality of life.
LUNSERS SWN SRA undesired SRA desired QoL
DAI-10 − .21⁎ .31⁎ − .25⁎ .50⁎ .30⁎
LUNSERS − .49⁎ .68⁎ .06 − .58⁎
SWN − .35⁎ .25⁎ .78⁎
SRA undesired .11 − .46⁎
SRA desired .25⁎
⁎pb .01.
DAI = Drugs Attitude Inventory; LUNSERS = Liverpool University Neuroleptic
Side Effect Rating Scale; SWN= SubjectiveWell-being on Neuroleptics; SRA=
Subjects' Response to Antipsychotics questionnaire: desired (recovery) and
undesired; QoL = Quality of life (WHOQoL-Bref).
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diagnosis of schizophrenia or schizo-affective disorder
according to DSM-IV criteria, along with treatment with
antipsychotic medication for at least six weeks. Patients
needed to be willing and able to understand the purpose of
the study and to give informed consent. Exclusion criteria
were the use of lithium or antidepressant medication. Their
mean age was 35 years (SD 11.5). Of the patients, 25.5% used
classic antipsychotic medication, 23.5% risperidone, 22.5%
clozapine, 19.0% olanzapine and 9.5% used quetiapine. Only 17
patients (5.3%) used two different antipsychotic medications.
Other co-medication (mainly benzodiazepines, N=72) was
taken by 126 patients. The duration of antipsychotic medica-
tion use was more than one year for 76% of the patients.
All patients were able to complete the questionnaires;
most (90%) did not need any assistance. They had to ﬁll in the
four above-mentioned self-rating scales on the effects of
antipsychotic medication. In addition, a quality of life (QoL)
scale had to be ﬁlled in, that is, the WHOQoL-BREF from the
World Health Organization (The WHOQOL Group, 1998).
Brieﬂy, the WHOQoL-BREF is a 26-item self-report question-
nairewith aﬁve-point Likert scale ranging from(1) “not at all/
very poor” to (5) “an extreme amount/very good.” The total
score ranges from 26 to 140, with higher scores indicating a
better quality of life. The WHOQoL-BREF deﬁnes QoL as an
individual's perceptions of their position in life in the context
of the culture and value systems in which they live and in
relation to their goals, expectations, standards and concerns. This
deﬁnition reﬂects theviewthatqualityof life refers to a subjective
evaluation that is embedded in a cultural, social and environ-
mental context. The WHOQOL-BREF has good to excellent
psychometric properties (Skevington et al., 2004).
2.2. Statistics
The subscales of all the instruments were constructed
according to the instructions of their respective developers.Internal consistency was calculated for all scales using
Cronbach's alpha (Cronbach, 1951), with a coefﬁcient of at
least 0.70 taken as acceptable (Cicchetti, 1994). Spearman
correlations were calculated for the association between the
self-rating scales and subscales for effects andWHOQol-BREF.
Data were analyzed in SPSS, version 14.
3. Results
Table 1 shows information about the aims, number of items
and subscales, completion time and internal consistency.
Completion time varies between 10 and 20 min without any
report ofmuch help needed. The internal consistency of total and
subscale scores is inmost casesmoderate to verygood, except for
the DAI-10.
Most correlations are signiﬁcant as expected. Table 2
provides the correlations between the self-rating scales. The
DAI-10 is moderately positively correlated with the desired
SWN and the SRA desired (.50) but less negatively with
LUNSERS and SRA undesired, thus indicating that the DAI is
picking up the more favorable responses instead of the
negative responses. The LUNSERS is quite strongly correlated
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SRA desired, thus indicating only overlap in the measurement
of negative experiences. The SWN shows its highest correla-
tion with the LUNSERS (− .49). The SRA is most strongly
associated with the LUNSERS (.68; SRA undesired) and the
DAI-10 (.50; SRA desired).
3.1. Association with the subjective quality of life
All scales are signiﬁcantly correlated with quality of life as
measured with the WHOQoL-BREF. SWN has a particularly
high (positive) correlation (.78), which means that well-
being and quality of life are almost identical. A negative
association is found with the LUNSERS (− .58) and the SRA
undesired (− .46) and a small positive association occurred
with the DAI-10 (.30) and the SRA desired (.25).
4. Discussion
This study shows that the DAI-10, LUNSERS, SWN and SRA
differ in scope, objectives, number of items and subscales, but
all have good to excellent internal consistency (.64–.93 for
total and subscales), except for the DAI-10 (.52). All could be
completed by more than 90% of the patients who agreed to
participate in the study, without help and in less than 20 min.
The psychometric qualities of the instruments as found in
this study are in line with earlier studies for the SWN and
LUNSERS. The original 30-item version of the DAI had good
internal (.93) and test–retest reliability (.82), but this was
never replicated for the DAI-10. This has been the ﬁrst study
of the psychometric qualities of the SRA.
Although all scales aim at measuring the effects of
antipsychotic medication, there are clear differences as to
internal consistency, and concurrent and conceptual validity.
The DAI-10 is a complicated scale in terms of evaluating the
different conceptual aspects of antipsychotic treatment, not
only vis-à-vis side effects, but also knowledge and attitudes
towards treatment. This has resulted in a low internal
consistency. The highest correlation is with the desired SRA,
indicating an association with positive aspects instead of the
negative side effects of the medication. Although the majority
of the patients are able to complete the DAI without help
within 5 min, the lack of internal consistency and its weak
association with QoL will limit its use in evaluating drug
treatment in clinical practice and treatment research.
The LUNSERS is a reliable scale for evaluating several
dimensions of the undesired side effects of treatment with
antipsychotics and it has the highest associationwith the SRA
undesired (concurrent validity). More undesired treatment
effects are associated with a lower score on QoL and SWN.
However, several negative experiences as recorded in these
items could also have other origins besides antipsychotic
treatment (e.g., constipation or weight loss). Therefore, the
LUNSERS may overestimate the frequency of side effects.
The SWN has good psychometric qualities and evaluates,
in line with its name, the well-being of patients. It is difﬁcult
to see how the items are linked to the positive or negative
effects of treatment in general and to antipsychotic treatment
in particular. The high correlation with the WHOQoL-BREF,
therefore, is not surprising and the SWN could in fact be
considered an alternative for a quality of life instrument inthis population. The SWN may be less suitable for evaluating
drug treatment in clinical practice.
The SRA evaluates desired (one dimension) as well as
undesired (several dimensions) treatment effects as attrib-
uted by the patient to his/her antipsychotic treatment. This
attribution has advantages and disadvantages: is the patient
indeed capable of making such statements, or might his lack
of insight be biasing his response by externalizing his negative
feelings about his condition to the medication? In other cases,
it has been established that patients with schizophrenia are
quite capable of making balanced attributions of effects to
their antipsychotic medication (Wolters et al., 2006). The SRA
and its various subscales may be useful in clinical practice in
order to assist in optimizing treatment with antipsychotics, as
well as in research concerning patient preferences, compli-
ance and pharmacology.
This study had quite a high number of patients (n=320),
but no follow-up (therefore, no test–retest reliabilities) and
no objective assessment of side effects by a psychiatrist.
This is one limitation of this study. Another limitation lies
possibly in the selection of patients. All were willing to be
treated with antipsychotics and to participate in this study.
They had to be able to concentrate, read and respond to a
large number of questions. The results could end up being
different for less compliant patients or for patients with
other diagnoses.
5. Conclusion
Taking into account the limitations of the study, we can
conclude that because of its weak psychometric qualities the
DAI-10 is not to be recommended for evaluating antipsychotic
drug treatment. Its strength lies in measuring compliance and
attitudes towards antipsychotic treatment. The LUNSERS may
be very useful for extensive screening of the side effects of
antipsychotic treatment, with the caveat of overestimating
the frequency of these effects. The SWN is to be recom-
mended as an alternative for a QoL instrument in patients
using antipsychotic medication. The SRA can be recom-
mended if a clinician or researcher is speciﬁcally interested
in undesired, as well as desired, responses attributed to the
antipsychotic medication, although one should keep in mind
that only the opinion of the patient should be recorded. This is
a limitation found in all four self-rating scales.
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